(MedPage Today) -- The FDA has expanded the approved use of ibrutinib (Imbruvica) in chronic lymphocytic leukemia to include patients with a chromosome 17p deletion, the agency announced today. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment